Agastiya Biotech
Agastiya Biotech
  • Media
  • Careers
  • Contact
  • Home
  • Pipeline
  • Technology
    • AB001: Gene Silencing Immunotherapy
    • ABREV001: pan-Mutated KRAS
  • Clinical Trials
  • About
Select Page

Agastiya Biotech to Bridge U.S. – India Drug Development

by Agastiya Biotech | Jul 9, 2019 | Media

Dr. Baskaran Pillai announces the launch of Agastiya Biotech, a biotechnology and new drug development company based in Temecula, CA.  Prior to Agasitya Biotech, Dr. Pillai started East West Integrative Research Institute in Chennai, India in 2013, which successfully...

Recent Posts

  • Vopec Pharmaceuticals and Agastiya Biotech Announce Breakthrough Phase 1 Study Results of Small Molecule AB001 for Multiple Metastatic Solid Tumors
  • Agastiya Biotech receives FDA Orphan Drug Designation for AB001 for Pancreatic cancer and Acute Myeloid Leukemia (AML)
  • Introducing Quantum Medicine to the World
  • Agastiya Biotech Proceeding with Drug Candidate for COVID-19: Small Molecule Compound for Treatment of SARS-CoV-2
  • Vopec gets NOC & test license from DCGI to develop new cancer drug that offers therapeutic option for COVID-19

Recent Comments

    Archives

    • April 2024
    • May 2022
    • January 2022
    • April 2020
    • March 2020
    • February 2020
    • July 2019
    • December 2018

    Categories

    • Media

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Agastiya Biotech 

    • Home
    • Pipeline
    • Research
    • Clinical Trials
    • Presentations & Publications
    • About

    © 2026 All Rights Reserved